What is Notable Labs?
Notable Labs operates at the intersection of biotechnology and data science, focusing on the critical challenge of drug efficacy in oncology. By prioritizing patient cohorts with significant unmet medical needs, the company utilizes its platform to accurately predict which pharmaceutical compounds or combination therapies will yield the highest success rates. Unlike traditional drug development models that prioritize broad market reach, Notable Labs emphasizes precision, effectively identifying high-probability treatment pathways for specific blood cancer profiles. This methodology not only accelerates the clinical validation process but also provides a scalable framework for personalized medicine, positioning the firm as a pivotal player in the evolution of targeted cancer therapies.
How much funding has Notable Labs raised?
Notable Labs has raised a total of $57.4M across 6 funding rounds:
Angel/Seed
$6M
Other Financing Round
$50K
Series A
$10M
Series B
$40M
Debt
$350K
Debt
$1M
Angel/Seed (2015): $6M with participation from First Round Capital, Y Combinator, Accelerate Brain Cancer Cure, Eric Kwan, 11.2 Capital, UpHonest Capital, and Refactor Capital
Other Financing Round (2016): $50K led by Undisclosed
Series A (2017): $10M supported by Builders VC
Series B (2019): $40M featuring Lifeforce Capital Gp I and B Capital Group
Debt (2020): $350K backed by PPP
Debt (2021): $1M with participation from PPP
Key Investors in Notable Labs
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions, particularly within the healthcare and technology sectors.
B Capital Group
B Capital is a global venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology and Healthcare sectors.
What's next for Notable Labs?
With the support of its latest major strategic investment, Notable Labs is well-positioned to scale its operational capabilities and expand its clinical research footprint. The company is expected to leverage this capital to deepen its predictive analytics infrastructure and potentially broaden its therapeutic focus beyond current blood cancer applications. As the firm transitions into a more mature lifecycle stage, the focus will likely shift toward strategic partnerships with pharmaceutical incumbents and the acceleration of its internal pipeline. By maintaining its commitment to data-driven drug selection, Notable Labs aims to redefine the standard of care for complex oncological conditions, ensuring that therapeutic interventions are both highly effective and precisely matched to individual patient needs.
See full Notable Labs company page
